Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateAccesswire • 11/02/23
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual MeetingAccesswire • 11/02/23
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of DirectorsAccesswire • 10/30/23
Protagonist Therapeutics: There Are Reasons Behind Johnson & Johnson's OptimismSeeking Alpha • 09/22/23
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAccesswire • 08/03/23
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque PsoriasisAccesswire • 07/04/23
Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 06/30/23
Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should KnowZacks Investment Research • 06/15/23
Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep goingZacks Investment Research • 06/13/23
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PVAccesswire • 06/09/23
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) CongressAccesswire • 06/06/23
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare ConferenceAccesswire • 06/01/23
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%Zacks Investment Research • 05/26/23
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113PRNewsWire • 05/12/23
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences ConferencePRNewsWire • 05/11/23